Brief: IDEAYA Reports Positive Phase 1/2 Data for IDE397 + Trodelvy in MTAP-Deleted Urothelial Cancer
08/09/2025 13:15
Sept 8 (Reuters) - IDEAYA Biosciences Inc IDYA.O: IDEAYA BIOSCIENCES ANNOUNCES POSITIVE DATA FROM PHASE 1/2 COMBINATION TRIAL OF IDE397, A POTENTIAL FIRST-IN-CLASS MAT2A INHIBITOR, AND TRODELVY® IN MTAP-DELETION UROTHELIAL CANCER IDEAYA BIOSCIENCES INC - MANAGEABLE SAFETY PROFILE IN IDE397 AND TRODELVY TRIAL Source text: ID:nPn7LdYz9a Further company coverage: IDYA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on IDEAYA Biosciences
See all newsBrief: Ideaya Biosciences And Servier Announce Data From Three Clinical Trials At Esmo 2026 Supporting The Potential Of Darovasertib To Become A Foundational New Therapy For Patients Across The Treatment Journey Of Uveal Melanoma
Brief: Ideaya Biosciences Announces The Promotion Of Dr. Michael White To President, Research And Development
Brief: Ideaya Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Ideaya Biosciences Inc Reports Results For The Quarter Ended June 30: Earnings Summary
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj